1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI)
about
Global phenotypic screening for antimalarialsStudies ofToxoplasma gondiiandPlasmodium falciparumenoyl acyl carrier protein reductase and implications for the development of antiparasitic agentsCrystal structure of enoyl-acyl carrier protein reductase (FabK) fromStreptococcus pneumoniaereveals the binding mode of an inhibitorIdentification and Development of Novel Inhibitors of Toxoplasma gondii Enoyl ReductaseStructural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) InhibitorsA Multilayer Network Approach for Guiding Drug Repositioning in Neglected DiseasesChallenges of antibacterial discoveryDiscovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matchingIdentification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductaseNovel targets for the future development of antibacterial agents.Fatty acid biosynthesis as a target for novel antibacterials'FAS't inhibition of malaria.Plasmid selection in Escherichia coli using an endogenous essential gene marker.Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemiaThe Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.Recent progress in coupling of two heteroarenes.Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniaeAG205, a novel agent directed against FabK of Streptococcus pneumoniae.Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.Mutagenicity assay in Salmonella for thirteen 2-substituted-1 H-phenanthro (9,10-d) imidazoles.Synthesis and bioassay of a new class of furanyl-1,3,4-oxadiazole derivatives.Synthesis and biological evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.Design, Synthesis, SAR and Molecular Modeling Studies of Novel Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives as Highly Potent Antimicrobial Agents.Rational questing for potential novel inhibitors of FabK from Streptococcus pneumoniae by combining FMO calculation, CoMFA 3D-QSAR modeling and virtual screening.Controllable access to multi-substituted imidazoles via palladium(ii)-catalyzed C-C coupling and C-N condensation cascade reactions.
P2860
Q26824875-3F5EF182-8A59-4137-816E-76CDB2E9B1BFQ27643926-76554B4B-AFA6-45C7-A53C-D4030D440029Q27649956-ABED0290-6376-470C-9C1B-84D00E80E70FQ27664019-0AEB3D08-577F-49EA-B88E-841537892583Q27679331-69F35468-366B-4710-B3CE-24ED7DA6555EQ28552140-119EE31C-A753-4027-9CEA-CF8ECF6301BDQ33793074-E3C47C4B-F5F6-4FAD-B86D-344C97A963D1Q34078440-30450A7E-1B30-42CF-BD1C-179809046CA5Q34315832-0727203A-6320-4A63-A3B9-EBF97669944EQ34631428-230CF9FB-CB45-4B7E-881C-EDF60B49E334Q35713880-C5A8B68A-A2B9-4664-83A8-2EE345FBE9B7Q35865145-5C0FDDC7-A398-43F7-96C1-4AC6C1A5071AQ36856568-50F959FA-18F6-4F40-B987-F0056806225EQ37383936-0AA7E568-851F-44A8-A873-9E63A3BA0034Q37544698-9070BBC9-61CB-4496-A13A-4B5E12EC1395Q37867064-010CCEA2-A606-42F0-8DBC-0891F1991FDEQ38124842-1063B63C-22B6-422B-8532-E3992B6E7505Q38765020-7A38E1E3-F70C-447B-9772-54D6595D68A6Q41870694-DD848CB5-3185-4413-892A-82BE9928041CQ42112414-7DD83312-D233-4B87-93BA-C35457032F8AQ42237853-49C98B8D-80B5-4666-912F-34B35AF051E3Q44634569-1380C710-F589-4982-BC03-9332A4D9C5BCQ45838363-AA5BD153-2357-4752-93D3-38865293976BQ45930405-861EB1D7-D983-4BAC-8556-65C7521FFCB8Q47710689-54455EED-9980-4810-8DC6-E2CCDA361649Q51658617-095FB908-C337-4E2B-B7FD-A4B5804AF9FAQ53099883-42850C3D-2803-4E3E-84AA-95DE154983BF
P2860
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI)
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@ast
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@en
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@nl
type
label
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@ast
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@en
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@nl
prefLabel
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@ast
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@en
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@nl
P2093
P1476
1,4-Disubstituted imidazoles a ...... rrier protein reductase (FabI)
@en
P2093
A P Fosberry
C A Janson
C Slater-Radosti
D A Heerding
D D Jaworski
D T Takata
P304
P356
10.1016/S0960-894X(01)00404-8
P407
P577
2001-08-20T00:00:00Z